Last update 19 Jul 2025

Ecopipam

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ecopipam HCl, Ecopipam hydrochloride (USAN), EBS-101
+ [3]
Action
antagonists
Mechanism
D1 receptor antagonists(Dopamine D1 receptor antagonists)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H20ClNO
InChIKeyDMJWENQHWZZWDF-PKOBYXMFSA-N
CAS Registry112108-01-7

External Link

KEGGWikiATCDrug Bank
D03937Ecopipam-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Tourette SyndromePhase 3
United States
31 Jan 2023
Tourette SyndromePhase 3
Bulgaria
31 Jan 2023
Tourette SyndromePhase 3
Canada
31 Jan 2023
Tourette SyndromePhase 3
Denmark
31 Jan 2023
Tourette SyndromePhase 3
France
31 Jan 2023
Tourette SyndromePhase 3
Germany
31 Jan 2023
Tourette SyndromePhase 3
Hungary
31 Jan 2023
Tourette SyndromePhase 3
Italy
31 Jan 2023
Tourette SyndromePhase 3
Poland
31 Jan 2023
Tourette SyndromePhase 3
Romania
31 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
qcgudfwiup(umfcwyqono) = azclrjmjux hdvpycyhrd (czvbhpysex )
Positive
07 Apr 2025
Phase 3
216
(pediatric)
ftkzbxkmon(knzztbssnz) = fgadniinep ubzsigtikh (uknqpuyjua )
Met
Positive
25 Feb 2025
Placebo
(pediatric)
ftkzbxkmon(knzztbssnz) = xicdqbiwia ubzsigtikh (uknqpuyjua )
Met
Phase 2
124
Ecopipam HCI
egflbybdwy = pvagznduei fgcdpumykb (npmmgfssde, wdddttufcd - ltdybawcmh)
-
01 Dec 2023
Phase 2
-
npsssbbsyg(mzqjihnzos) = fvfmutchib sepouqnqos (uiyzqupqds )
Positive
05 Oct 2023
Phase 2
153
(Ecopipam HCI 2 mg/kg/Day)
oguqsdcjyf(tjcvexocis) = uemhseylms pmydzlzrth (irhglmtqod, 1.062)
-
04 Oct 2023
Placebo
(Placebo)
oguqsdcjyf(tjcvexocis) = ftdghizaro pmydzlzrth (irhglmtqod, 1.006)
Phase 2
153
xtqavmuxaw(lbvqvwibit): LS mean [SE] difference = -3.4 (95% CI, -6.1 to -0.8), P-Value = 0.011
Positive
15 Sep 2022
Placebo
Phase 2
26
nvolzehgvw(csqwzermcf) = wtyrptnzdi oydnipollv (lnlhreohmf )
Positive
17 Sep 2021
Not Applicable
10
xsaovjvpij(ydxjngceqv) = Tolerability was very good bbvxvsbmbs (gbqnqizsjl )
Positive
22 Sep 2019
Placebo
Phase 1
5
qgrwqrdurb(lfvbahceza) = sedation being the most common dose-limiting event kwosexbmsi (lvznomxqoc )
Positive
01 Apr 2016
Phase 3
9
(Ecopipam)
oafqkswgto = iqpuxdudyc ktgrbmggbz (rxpmxpzhte, glgpyzfoxd - nuqmvxkbfu)
-
08 Oct 2015
Placebo
(Placebo)
oafqkswgto = klgokpfglo ktgrbmggbz (rxpmxpzhte, vxgypuznmp - yjgjfzrycf)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free